Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Soligenix	Forward Pharma A/S	Cumberland Pharmaceuticals	Regulus Therapeutics	Akari Therapeutics
Symbol	NASDAQ:SNGX	NASDAQ:FWP	NASDAQ:CPIX	NASDAQ:RGLS	NASDAQ:AKTX
Price Information
Current Price	$1.51	$7.32	$3.17	$1.38	$2.41
52 Week Range	Buy	N/A	Buy	Hold	Buy
MarketRank™
Overall Score	1.4	0.7	0.9	0.9	1.4
Analysis Score	3.3	0.0	0.0	1.2	3.5
Community Score	2.9	2.8	2.2	2.9	2.7
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	0.0	0.8	0.0	0.8
Earnings & Valuation Score	0.6	0.6	1.3	0.6	0.0
Analyst Ratings
Consensus Recommendation	Buy	N/A	Buy	Hold	Buy
Consensus Price Target	$3.44	N/A	N/A	$1.25	$5.00
% Upside from Price Target	127.65% upside	N/A	N/A	-9.42% downside	107.47% upside
Trade Information
Market Cap	$60.43 million	$49.71 million	$47.30 million	$100.06 million	$38.22 million
Beta	1.42	1.85	0.32	2.41	1.52
Average Volume	4,028,264	65,254	64,520	3,092,655	235,938
Sales & Book Value
Annual Revenue	$4.60 million	N/A	$47.53 million	$6.83 million	N/A
Price / Sales	13.14	N/A	1.00	14.65	N/A
Cashflow	N/A	N/A	$0.51 per share	N/A	N/A
Price / Cash	N/A	N/A	6.25	N/A	N/A
Book Value	$0.07 per share	$11.42 per share	$3.36 per share	$0.95 per share	($0.11) per share
Price / Book	21.57	N/A	0.94	1.45	N/A
Profitability
Net Income	$-9,360,000.00	$-4,220,000.00	$-3,540,000.00	$-18,590,000.00	$-17,110,000.00
EPS	($0.48)	N/A	$0.23	($1.08)	($0.93)
Trailing P/E Ratio	N/A	0.00	N/A	N/A	N/A
Forward P/E Ratio	N/A	∞	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-567.04%	N/A	-8.36%	N/A	N/A
Return on Equity (ROE)	-328.25%	N/A	3.86%	-150.66%	-880.38%
Return on Assets (ROA)	-140.08%	N/A	1.92%	-57.52%	-161.52%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.02%	N/A	0.31%	N/A	N/A
Current Ratio	2.30%	118.57%	2.04%	1.35%	1.55%
Quick Ratio	2.30%	N/A	1.62%	1.35%	1.55%
Ownership Information
Institutional Ownership Percentage	9.39%	12.88%	26.15%	19.96%	9.20%
Insider Ownership Percentage	3.09%	N/A	39.72%	18.24%	61.80%
Miscellaneous
Employees	15	5	90	24	10
Shares Outstanding	40.02 million	6.79 million	14.92 million	72.51 million	15.86 million
Next Earnings Date	5/21/2021 (Estimated)	4/23/2021 (Estimated)	5/19/2021 (Estimated)	5/13/2021 (Estimated)	6/4/2021 (Estimated)
Optionable	Not Optionable	Not Optionable	Optionable	Optionable	Not Optionable

Source	Headline
	Akari Therapeutics (NASDAQ:AKTX) Stock Price Passes Below 50-Day Moving Average of $3.02 americanbankingnews.com - April 6 at 2:58 AM
	Akari Therapeutics, Plc (NASDAQ:AKTX) Short Interest Update americanbankingnews.com - March 28 at 3:30 AM
	AKARI THERAPEUTICS PLC(AKTX) fool.com - March 21 at 8:10 AM
	Akari Therapeutics, Plc (NASDAQ:AKTX) Short Interest Down 28.0% in February americanbankingnews.com - March 18 at 1:38 AM
	Short Interest in Akari Therapeutics, Plc (NASDAQ:AKTX) Declines By 28.0% americanbankingnews.com - March 16 at 1:14 AM
	BRIEF—Akari’s nomacopan to be studied in civilian and battlefield trauma thepharmaletter.com - March 5 at 10:10 AM
	Akari Therapeutics Announces a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) for Nomacopan in Trauma finance.yahoo.com - March 4 at 10:03 AM
	Akari Therapeutics' PASylated Nomacopan Shows Promising Action In Animal Studies finance.yahoo.com - February 25 at 8:25 PM
	Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting ... apnews.com - February 25 at 9:28 AM
	Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting PASylated Nomacopan to Treat Retinal Diseases, Including Age-Related Macular Degeneration (AMD) and Uveitis finance.yahoo.com - February 25 at 9:28 AM
	Is Akari Therapeutics, Plc (NASDAQ:AKTX) Popular Amongst Insiders? finance.yahoo.com - February 2 at 8:03 AM
	Akari Therapeutics Adds Histamine Inhibitor Votucalis to Pipeline to treat Neuropathic Pain and Dermatological Disease finance.yahoo.com - February 1 at 9:47 AM
	Akari Therapeutics to Participate in Two January Virtual Investor Conferences finance.yahoo.com - January 6 at 9:53 AM
	Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress morningstar.com - December 11 at 10:32 AM
	Akari Therapeutics Announces New Clinical Data that Show Long-Term Self-Administered Nomacopan is Well-Tolerated and Substantially Reduces Transfusion Dependence in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) finance.yahoo.com - December 11 at 10:32 AM
	Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress finance.yahoo.com - December 11 at 10:31 AM
	Akari Therapeutics Announces Publication in American Journal of Pathology Highlighting Potential of Nomacopan in Treatment of Uveitis and Retinal Disease finance.yahoo.com - December 3 at 6:17 PM
	Akari Therapeutics (NASDAQ:AKTX) Will Have To Spend Its Cash Wisely finance.yahoo.com - December 1 at 8:11 AM
	Akari Therapeutics PLC (ADR) reuters.com - November 15 at 11:51 PM
	Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at European Academy ... apnews.com - October 28 at 7:44 PM
	Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at European Academy of Dermatology and Venereology (EADV) Virtual Congress October 29 finance.yahoo.com - October 27 at 1:07 PM
	Akari Therapeutics Reports Continued Progress In COVID-19 Pneumonia Program With Nomacopan markets.businessinsider.com - October 6 at 9:34 AM
	Akari's nomacopan to enter late-stage skin blistering disorder study during next year seekingalpha.com - October 1 at 2:42 PM
	Akari Therapeutics to Present Its Phase III Plans at the International Pemphigus & Pemphigoid Foundation (IPPF) Patient Education Conference nasdaq.com - September 29 at 12:10 PM
	Akari Therapeutics to Participate in Two September Virtual Investor Conferences finance.yahoo.com - September 10 at 9:19 AM

Date	Company	Brokerage	Action
1/28/2021	Soligenix	B. Riley	Reiterated Rating
12/23/2020	Soligenix	Alliance Global Partners	Lower Price Target
7/28/2020	Soligenix	Dawson James	Downgrade
6/25/2020	Soligenix	Maxim Group	Initiated Coverage
9/1/2020	Regulus Therapeutics	HC Wainwright	Reiterated Rating
7/24/2020	Regulus Therapeutics	Wedbush	Reiterated Rating
5/15/2020	Regulus Therapeutics	Needham & Company LLC	Initiated Coverage
3/19/2019	Regulus Therapeutics	Wells Fargo & Company	Lower Price Target

(Data available from 4/10/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources